Assessing drug distribution in tissues expressing P-glycoprotein through physiologically based pharmacokinetic modeling: Model structure and parameters determination

Theoretical Biology and Medical Modelling

Volumn 6, Issue 1, 2009, Pages

  Fenneteau, Frédérique ^a   Turgeon, Jacques ^a   Couture, Lucie ^a,b   Michaud, Véronique ^a   Li, Jun ^a,c   Nekka, Fahima ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b CHARLES RIVER LABORATORIES   (United States)

^c Pharsight   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DIGOXIN; DOMPERIDONE; GLYCOPROTEIN P; PACLITAXEL; RIFAMPICIN; SAQUINAVIR; TALINOLOL; TOPOTECAN; VERAPAMIL;

ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BODY WEIGHT; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG TRANSPORT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PARAMETERS OF MEASUREMENT AND ANALYSIS; PROTEIN EXPRESSION; TISSUE DISTRIBUTION; ANIMAL; CELL STRAIN CACO 2; METABOLISM; PERMEABILITY; PHARMACOKINETICS; THEORETICAL MODEL;

ANIMALS; CACO-2 CELLS; HUMANS; MICE; MODELS, THEORETICAL; P-GLYCOPROTEIN; PERMEABILITY; PHARMACOKINETICS; TISSUE DISTRIBUTION;

EID: 63349101281     PISSN: None     EISSN: 17424682     Source Type: Journal    
DOI: 10.1186/1742-4682-6-2     Document Type: Article

References (60)

1. Role of transport proteins in drug absorption, distribution and excretion. A Ayrton P Morgan, Xenobiotica 2001 31 469 497 10.1080/ 00498250110060969 11569523
2. Importance of P-glycoprotein for drug disposition in humans. MF Fromm, Eur J Clin Invest 2003 33 6 9 10.1046/j.1365-2362.33.s2.4.x 14641550
3. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug transporting) P-glycoproteins. AH Schinkel U Mayer E Wagenaar CAAM Mol L van Deemter JJM Smit MA van der Valk AC Voordouw H Spits O van Tellingen JMJM Zilmans WE Fibbe P Borst, Proc Natl Acad Sci 1997 94 4028 4033 9108099 10.1073/pnas.94.8.4028
4. Disruption of the mouse mdr1a P-glycoprotein gene to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. AH Schinkel JJ Smit O van Tellingen J Beijnen E Wagenaar L van Deemter CA Mol MA van der Valk EC Robanus-Maandag HP te Riele, Cell 1994 77 491 502 10.1016/0092-8674(94)90212-7 7910522
5. Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein. J van Asperen O van Tellingen F Tijssen AH Schinkel J Beijnen, Br J Cancer 1999 79 108 113 10.1038/sj.bjc.6690019 10408701
6. Age-related differences in vincristine toxicity and biodistribution in wild-type and transporter-deficient mice. T Muramatsu DR Johnson RA Finch LK Johnson JJ Leffert ZP Lin G Pizzorno AC Sartorelli, Oncol Res 2004 14 331 343 15301424
7. Multidrug resistance and the role of P-glycoprotein knockout mice. AH Schinkel CA Mol E Wagenaar L van Deemter JJ Smit P Borst, Eur J Cancer 1995 31A 1295 8 10.1016/0959-8049(95)00130-B 7577039
8. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. AH Schinkel E Wagenaar L van Deemter CA Mol P Borst, J Clin Invest 1995 96 1698 705 7560060 10.1172/JCI118214
9. Interaction of warfarin with drugs, natural substances, and foods. DJ Greenblatt LL von Moltke, J Clin Pharmacol 2005 45 127 132 10.1177/ 0091270004271404 15647404
10. Prevention of food-drug interactions with special emphasis on older adults. BJ McCabe, Curr Opin Clin Nutr Metab Care 2004 7 21 26 10.1097/00075197-200401000-00005 15090899
11. Dietary effects on drug metabolism and transport. RZ Harris GR Jang S Tsunoda, Clin Pharmacokinet 2003 42 1071 1088 10.2165/00003088-200342130-00001 14531721
12. Whole Body Pharmacokinetic Models. I Nestorov, Clin Pharmacokinet 2003 42 883 908 10.2165/00003088-200342100-00002 12885263
13. Physiologically Based Pharmacokinetic (PBPK) Modeling of Dispposition of Epiroprim in Humans. O Luttringer F Theil P Poulin A Schmitt-Hoffmann T Guentert T Lave, J Pharm Sci 2003 92 1990 2007 10.1002/jps.10461 14502539
14. Physiologically based pharmacokinetics in drug development and regulatory science: a workshop report (Georgetown University, Washington, DC, May 29-30, 2002). M Rowland L Balant C Peck, AAPS PharmSci 2004 6 E6 10.1208/ps060106 15198507
15. Cardiac arrest after treatment with intravenous domperidone. HA Cameron AJ Reyntjens G Lake-Bakaar, Br Med J 1985 290 160 3917732
16. Cardiotoxicity of domperidone. N Quinn D Parkes G Jackson J Upward, lancet 1985 2863702
17. Cardiotoxicity of intravenous domperidone. RJ Osborne ML Slevin RW Hunter J Hamer, Lancet 1985 385 10.1016/S0140-6736(85)92515-2 2862531
18. Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. F Faassen G Vogel H Spanings H Vromans, Int J Pharm 2003 263 113 122 10.1016/S0378-5173(03)00372-7 12954186
19. Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. KS Pang M Rowland, J Pharmacokinet Biopharm 1977 5 625 53 10.1007/BF01059688 599411
20. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. T Rodgers D Leahy M Rowland, J Pharm Sci 2005 94 1259 76 10.1002/jps.20322 15858854
21. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and non specific binding to microsomes. RS Obach, Drug Met Disp 1999 27 1350 1359
22. The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. RP Austin P Barton SL Cockroft MC Wenlock RJ Riley, Drug Metab Dispos 2002 30 1497 503 10.1124/dmd.30.12.1497 12433825
23. Prediction of Pharmacokinetics prior to in Vivo Studies. II. Generic Physiologically Based Pharmacokinetic Models of Drug Disposition. P Poulin F Theil, J Pharm Sci 2002 91 1358 1370 10.1002/jps.10128 11977112
24. The ATP-binding cassette transporters and their implication in drug disposition: a special look at the heart. L Couture JA Nash J Turgeon, Pharmacol Rev 2006 58 244 258 10.1124/pr.58.2.7 16714487
25. Physiologically parameter values for physiologically based pharmacokinetic models. RP Brown MD Delp SL Lindstedt LR Rhomberg RP Beliles, Toxicol Ind Health 1997 13 407 483 9249929
26. A priori Prediction of Tissue:Plasma Partition Coefficients of Drugs to Facilitate the Use of Physiologically-Based Pharmacokinetic Models in Drug Discovery. P Poulin F Theil, J Pharm Sci 2000 89 16 35 10.1002/(SICI)1520- 6017(200001)89:1<16::AID-JPS3>3.0.CO;2-E 10664535
27. Prediction of Adipose Tissue:Plasma Partition Coefficients for Structurally Unrelated Drugs. P Poulin K Schoenlein F Theil, J Pharm Sci 2001 90 436 447 10.1002/1520-6017(200104)90:4<436::AID-JPS1002>3.0.CO;2-P 11170034
28. Interspecies considerations in the evaluation of human food safety for veterinary drugs. AL Craigmill KA Cortright, AAPS Pharm Sci 2002 4 E34 10.1208/ps040434
29. Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier. S Cisternino C Mercier F Bourasset F Roux JM Scherrmann, Cancer Res 2004 64 3296 3301 10.1158/0008-5472.CAN-03-2033 15126373
30. P-glycoprotein and mutlidrug resistance-associated proteins limit the brain uptake of saquinavir in mice. S Park PJ Sinko, J Pharmacol Exp Ther 2005 312 1249 56 10.1124/jpet.104.076216 15528451
31. Plasma and blood volumes of mouse organs, as determined with radioactive iodoproteins. N Kaliss D Pressman, Proc Soc Exp Biol Med 1950 75 16 20 14797719
32. Upregulation of the transport system for TNFalpha at the blood-brain barrier. W Pan AJ Kastin, Arch Physiol Biochem 2001 109 350 3 11935370
33. In vitro models for the blood-brain barrier. P Garberg M Ball N Borg R Cecchelli L Fenart RD Hurst T Lindmark A Mabondzo JE Nilsson TJ Raub D Stanimirovic T Terasaki JO Oberg T Osterberg, Toxicol In Vitro 2005 19 299 334 10.1016/j.tiv.2004.06.011 15713540
34. Potential error in the measurement of tissue to blood distribution coefficients in physiological pharmacokinetic modeling. Residual tissue blood. II. Distribution of phencyclidine in the rat. S Khor H Bozigian M Mayersohn, Drug Metab Dispos 1991 19 486 90 1676659
35. On the blood content of guinea-pig tissues. JA Bosse O Wassermann, Pharmacology 1970 4 273 7 10.1159/000136147 5490474
36. RM Berne N Sperelakis, Handbook of physiology: the Cardiovascular System 1979
37. JE Riviere, Comparative Pharmacokinetics: Principles, Techniques, and Applications Blackwell Publishing Limited 1 1999
38. Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo. A Collett J Tanianis-Hughes D Hallifax G Warhurst, Pharm Res 2004 21 819 826 10.1023/B:PHAM.0000026434.82855.69 15180340
39. Limited oral biovailability abd active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. A Sparreboom J van Asperen U Mayer AH Schinkel JW Smit DK Meijer P Borst WJ Nooijen J Beijnen O van Tellingen, Proc Natl Acad Sci 1997 94 2031 2035 9050899 10.1073/pnas.94.5.2031
40. Substantial excretion of digoxin via the intestinal mucosa and prevention of long term digoxin accumulation in the brain by mdr1a P-glycoprotein. U Mayer E Wagenaar J Beijnen JW Smit DK Meijer J van Asperen P Borst AH Schinkel, Br J Pharmacol 1996 119 1038 44 8922756
41. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. RB Kim MF Fromm C Wandel B Leake AJ Wood DM Roden GR Wilkinson, J Clin Invest 1998 101 289 94 9435299 10.1172/JCI1269
42. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. JW Jonker JW Smit RF Brinkhuis M Maliepaard JH Beijnen JH Schellens AH Schinkel, J Natl Cancer Inst 2000 92 1651 6 10.1093/jnci/92.20.1651 11036110
43. DrugBank: a comprehensive resource for in silico drug discovery and exploration. D Wishart C Knox A Guo S Shrivastava M Hassanali P Stothard Z Chang J Woolsey, Nucleic Acids Res 2006 34 D668 72 16381955 10.1093/nar/gkj067
44. PubChem. http://pubchem.ncbi.nlm.nih.gov/
45. The role of P-glycoprotein in determining the oral absorption and clearance of the NK2 antagonist, UK-224,671. K Beaumont A Harper DA Smith J Bennett, Eur J Pharm Sci 2000 12 41 50 10.1016/S0928-0987(00)00144-5 11121732
46. Comparison of in vitro and in vivo models of drug transcytosis trhough the blood brain barrier. WM Pardridge D Triguero J Yang PA Cancilla, J Pharmacol Exp Ther 1990 253 884 891 2338660
47. Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells. VD Makhey A Guo DA Norris P Hu J Yan PJ Sinko, Pharm Res 1998 15 1160 1167 10.1023/A:1011971303880 9706044
48. Domperidone: A peripherally Acting Dopamine2-receptor antagonist. JA Barone, Ann Pharmacol 1999 33 429 440 10.1345/aph.18003
49. U.S Environmental Protection Agency: Exposure Assessment Tools and Models. 2005 http://www.epa.gov/opptintr/exposure/pubs/episuite.htm
50. On the pharmacokinetics of domperidone in animals and man. I. Plasma levels of domperidone in rats and dogs. Age related adsorption and passage through the blood brain barrier in rats. J Heykants A Knaeps W Meuldermans M Michiels, Eur J Drug Met Pharmacokinet 1981 6 27 36
51. Comparison of drug transporter gene expression and functionality in Caco-2 cells from 10 different laboratories. R Hayeshi C Hilgendorf P Artursson P Augustijns B Brodin P Dehertogh K Fisher L Fossati E Hovenkamp T Korjamo C Masungi N Maubon R Mols A Mullertz J Monkkonen C O'Driscoll HM Oppers-Tiemissen EG Ragnarsson M Rooseboom AL Ungell, Eur J Pharm Sci 2008 18782614
52. Variability in mRNA expression of ABC- and SLC-transporters in human intestinal cells: comparison between human segments and Caco-2 cells. A Seithel J Karlsson C Hilgendorf A Bjorquist AL Ungell, Eur J Pharm Sci 2006 28 291 9 10.1016/j.ejps.2006.03.003 16704924
53. Blood-brain barrier efflux transport. PL Golden GM Pollack, J Pharm Sci 2003 92 1739 1753 10.1002/jps.10424 12949994
54. Potential role of ABC transporters as a detoxification system at the blood-CSF barrier. EC de Lange, Adv Drug Deliv Rev 2004 56 1793 809 10.1016/j.addr.2004.07.009 15381334
55. Quantitative exposure assessment: application of physiologically-based pharmacokinetic (PBPK) modeling of low-dose, long-term exposures of organic acid toxicant in the brain. CS Kim JA Sandberg W Slikker Z Binienda PM Schlosser TA Patterson, Environ Toxicol Pharmacol 2001 9 153 160 10.1016/S1382-6689(01)00060- 6 11292578
56. Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain. EC de Lange M Danhof, Clin Pharmacokinet 2002 41 691 703 10.2165/00003088-200241100-00001 12162757
57. Role of P-glycoprotein in restricting propranolol transport in cultured rabbit conjunctival epithelial cell layers. JJ Yang KJ Kim VH Lee, Pharm Res 2000 17 533 538 10.1023/A:1007508714259 10888304
58. Rational use of in vitro P-glycoprotein assays in drug discovery. JW Polli SA Wring JE Humphreys L Huang JB Morgan LO Webster CS Serabjit-Singh, J Pharmacol Exp Ther 2001 299 620 628 11602674
59. Resolution of P-glycoprotein and non P-glycoprotein effects on drug permeability using intestinal tissus from mdr1a(-/-) mice. RH Stephens CA O'Neill J Bennett M Humphrey B Henry M Rowland G Warhurst, Br J Pharmacol 2002 135 2038 2046 11959808 10.1038/sj.bjp.0704668
60. Physiologically based pharmacokinetics of digoxin in mdr1a knockout mice. M Kawahara A Sakata T Miyashita I Tamai A Tsuji, J Pharm Sci 1999 88 1281 7 10.1021/js9901763 10585223